Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apply for the Fierce AI Innovation Awards - Submissions close Thursday, June 18
mergers and acquisitions
Fierce Biotech
Astellas targets more deals, cost cutting to swerve patent cliff
Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing to tighten its belt.
James Waldron
May 26, 2026 7:35am
BioMarin lays off staffers at recently-acquired Amicus
May 12, 2026 5:12pm
Chiesi grows rare disease ambitions with $1.9B KalVista buyout
Apr 29, 2026 10:01am
Neurocrine pays $2.9B for Soleno, its largest M&A deal ever
Apr 6, 2026 10:30am
M&A surge triggers high expectations for 2026
Apr 6, 2026 5:00am
Veeva pays $100M for Ostro and its pharma-focused AI chat tool
Mar 11, 2026 11:55am
